Moderna (MRNA) concentration risks

The company's only disclosed concentration in the 10-K is a product-level exposure to COVID vaccines as the dominant revenue source. In 2025, total revenue of $1.9 billion was largely from sales of COVID vaccines — a moderate share by disclosed size with a structural character, reflecting the company's near-term dependence on a single vaccine franchise to sustain commercial revenue while its broader mRNA pipeline matures. The structural character acknowledges that this concentration is a known feature of the company's stage of development: the COVID vaccine franchise is the only product generating meaningful commercial revenue at the time of the filing, with the rest of the pipeline in various stages of clinical development. However, the dependency dimension is real — COVID vaccine demand has proven to be variable based on public health policy, seasonal uptake, and competitive alternatives, meaning the revenue line is less predictable than a diversified commercial portfolio would be. There is no disclosed customer, geographic, or supplier concentration separately presented in the available source claims that would layer additional idiosyncratic risk on top of this product-level tilt. On balance, the disclosed concentration profile is narrow: a moderate share tied to one product category whose demand outlook is tied to seasonal respiratory virus dynamics and public health guidance rather than to a commercial or counterparty relationship that could be contractually managed.

For the engine’s reasoning on MRNA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.